PAVmed Book Value Per Share from 2010 to 2024

PAVMZ Stock

USD 0.03 0.01 92.00%

PAVmed Series Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of PAVmed Series Z according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(3.32)

Current Value

(3.16)

Quarterly Volatility

4.48258786

Credit Downgrade

Yuan Drop

Covid

Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 559.5 K, Selling General Administrative of 32.5 M or Other Operating Expenses of 74.8 M, as well as many indicators such as Price To Sales Ratio of 11.54, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.

Check out the analysis of PAVmed Series Correlation against competitors.

Latest PAVmed Series' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of PAVmed Series Z over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. PAVmed Series' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (6.62) X

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

PAVmed Book Value Per Share Regression Statistics

	Arithmetic Mean	0.72
	Coefficient Of Variation	620.71
	Mean Deviation	2.56
	Median	0.84
	Standard Deviation	4.48
	Sample Variance	20.09
	Range	18.6894
	R-Value	(0.05)
	Mean Square Error	21.59
	R-Squared	0
	Significance	0.86
	Slope	(0.05)
	Total Sum of Squares	281.31

PAVmed Book Value Per Share History

	2024	-3.16
	2023	-3.32
	2022	1.84
	2021	15.37
	2020	-0.15
	2019	-2.3
	2018	-1.67

Other Fundumenentals of PAVmed Series Z

Tangible Book Value Per Share

PAVmed Series Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Property Plant Equipment	Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Short Long Term Debt	Capital Stock	Short Term Debt	Short Term Investments	Net Tangible Assets	Current Deferred Revenue	Net Receivables	Good Will	Intangible Assets
Total Assets		0.3	-0.58	-0.66	0.75	0.45	1.0	0.79	0.78	0.7	-0.66	-0.16	0.81	0.61	0.82	0.67	0.82	0.81	0.21	0.78	0.87	0.21	-0.43
Total Stockholder Equity	0.3		-0.94	0.51	-0.28	-0.7	0.38	0.47	0.1	-0.26	0.18	0.72	0.79	0.93	-0.23	-0.44	-0.23	-0.26	-0.74	-0.29	0.38	-0.74	0.7
Net Debt	-0.58	-0.94		-0.22	0.0	0.45	-0.65	-0.6	-0.31	0.01	0.04	-0.52	-0.92	-1.0	-0.08	0.17	-0.09	-0.04	0.52	-0.03	-0.65	0.52	-0.45
Retained Earnings	-0.66	0.51	-0.22		-0.92	-0.97	-0.6	-0.35	-0.66	-0.86	0.76	0.74	-0.11	0.18	-0.91	-0.96	-0.9	-0.92	-0.77	-0.91	-0.5	-0.77	0.92
Capital Surpluse	0.75	-0.28	0.0	-0.92		0.86	0.72	0.57	0.88	0.96	-0.91	-0.59	0.34	0.02	0.84	0.95	0.84	0.82	0.58	0.8	0.57	0.58	-0.72
Total Liab	0.45	-0.7	0.45	-0.97	0.86		0.39	0.2	0.56	0.8	-0.72	-0.8	-0.12	-0.42	0.78	0.93	0.78	0.81	0.8	0.8	0.27	0.8	-0.95
Total Current Assets	1.0	0.38	-0.65	-0.6	0.72	0.39		0.79	0.78	0.67	-0.64	-0.13	0.85	0.67	0.77	0.62	0.77	0.75	0.15	0.73	0.9	0.15	-0.35
Common Stock	0.79	0.47	-0.6	-0.35	0.57	0.2	0.79		0.8	0.57	-0.61	0.25	0.85	0.6	0.48	0.45	0.48	0.52	-0.26	0.38	0.47	-0.26	-0.16
Accounts Payable	0.78	0.1	-0.31	-0.66	0.88	0.56	0.78	0.8		0.86	-0.92	-0.21	0.61	0.31	0.64	0.73	0.64	0.62	0.19	0.56	0.57	0.19	-0.39
Property Plant Equipment	0.7	-0.26	0.01	-0.86	0.96	0.8	0.67	0.57	0.86		-0.88	-0.54	0.32	0.01	0.78	0.93	0.78	0.76	0.54	0.74	0.53	0.54	-0.67
Long Term Debt	-0.66	0.18	0.04	0.76	-0.91	-0.72	-0.64	-0.61	-0.92	-0.88		0.41	-0.37	-0.05	-0.67	-0.8	-0.67	-0.65	-0.41	-0.63	-0.46	-0.41	0.54
Long Term Debt Total	-0.16	0.72	-0.52	0.74	-0.59	-0.8	-0.13	0.25	-0.21	-0.54	0.41		0.35	0.48	-0.48	-0.63	-0.48	-0.49	-0.8	-0.55	-0.25	-0.8	0.74
Net Invested Capital	0.81	0.79	-0.92	-0.11	0.34	-0.12	0.85	0.85	0.61	0.32	-0.37	0.35		0.92	0.36	0.17	0.36	0.34	-0.36	0.28	0.72	-0.36	0.15
Net Working Capital	0.61	0.93	-1.0	0.18	0.02	-0.42	0.67	0.6	0.31	0.01	-0.05	0.48	0.92		0.11	-0.15	0.11	0.07	-0.5	0.06	0.68	-0.5	0.42
Short Long Term Debt	0.82	-0.23	-0.08	-0.91	0.84	0.78	0.77	0.48	0.64	0.78	-0.67	-0.48	0.36	0.11		0.9	1.0	0.97	0.68	0.99	0.68	0.68	-0.78
Capital Stock	0.67	-0.44	0.17	-0.96	0.95	0.93	0.62	0.45	0.73	0.93	-0.8	-0.63	0.17	-0.15	0.9		0.9	0.88	0.71	0.87	0.46	0.71	-0.85
Short Term Debt	0.82	-0.23	-0.09	-0.9	0.84	0.78	0.77	0.48	0.64	0.78	-0.67	-0.48	0.36	0.11	1.0	0.9		0.97	0.68	0.99	0.68	0.68	-0.78
Short Term Investments	0.81	-0.26	-0.04	-0.92	0.82	0.81	0.75	0.52	0.62	0.76	-0.65	-0.49	0.34	0.07	0.97	0.88	0.97		0.6	0.97	0.6	0.6	-0.86
Net Tangible Assets	0.21	-0.74	0.52	-0.77	0.58	0.8	0.15	-0.26	0.19	0.54	-0.41	-0.8	-0.36	-0.5	0.68	0.71	0.68	0.6		0.73	0.27	1.0	-0.75
Current Deferred Revenue	0.78	-0.29	-0.03	-0.91	0.8	0.8	0.73	0.38	0.56	0.74	-0.63	-0.55	0.28	0.06	0.99	0.87	0.99	0.97	0.73		0.68	0.73	-0.82
Net Receivables	0.87	0.38	-0.65	-0.5	0.57	0.27	0.9	0.47	0.57	0.53	-0.46	-0.25	0.72	0.68	0.68	0.46	0.68	0.6	0.27	0.68		0.27	-0.22
Good Will	0.21	-0.74	0.52	-0.77	0.58	0.8	0.15	-0.26	0.19	0.54	-0.41	-0.8	-0.36	-0.5	0.68	0.71	0.68	0.6	1.0	0.73	0.27		-0.75
Intangible Assets	-0.43	0.7	-0.45	0.92	-0.72	-0.95	-0.35	-0.16	-0.39	-0.67	0.54	0.74	0.15	0.42	-0.78	-0.85	-0.78	-0.86	-0.75	-0.82	-0.22	-0.75

Click cells to compare fundamentals

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(3.32)	(3.16)
Tangible Book Value Per Share	(3.52)	(3.34)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC